Mingowood Pharmacal

Mingowood PharmacalMingowood PharmacalMingowood Pharmacal
  • Sign In
  • Create Account

  • My Account
  • Signed in as:

  • filler@godaddy.com


  • My Account
  • Sign out

  • Home
  • Technology
    • Our Science
    • Demonstration
    • Stability Studies
    • ATR-FTIR
    • Patents
    • FAQ
  • Solutions
    • For Pharma & Biotech
    • For Manufacturers
    • For Investors
  • Pipeline
  • About
    • Mission
    • The Problem We Solve
    • Licensing Model
    • Leadership
  • News
  • Contact
  • More
    • Home
    • Technology
      • Our Science
      • Demonstration
      • Stability Studies
      • ATR-FTIR
      • Patents
      • FAQ
    • Solutions
      • For Pharma & Biotech
      • For Manufacturers
      • For Investors
    • Pipeline
    • About
      • Mission
      • The Problem We Solve
      • Licensing Model
      • Leadership
    • News
    • Contact

Mingowood Pharmacal

Mingowood PharmacalMingowood PharmacalMingowood Pharmacal

Signed in as:

filler@godaddy.com

  • Home
  • Technology
    • Our Science
    • Demonstration
    • Stability Studies
    • ATR-FTIR
    • Patents
    • FAQ
  • Solutions
    • For Pharma & Biotech
    • For Manufacturers
    • For Investors
  • Pipeline
  • About
    • Mission
    • The Problem We Solve
    • Licensing Model
    • Leadership
  • News
  • Contact

Account


  • My Account
  • Sign out


  • Sign In
  • My Account

The only patented technology that stabilizes acidic cannabinoids for pharmaceutical, wellness, and consumer applications.

  

Mingowood Pharmacal’s patented Intercalyx™ platform solves the instability problem that has blocked acidic cannabinoid therapeutics for decades. Patented. Scalable. Regulatory-friendly.

Explore Licensing OpportunitiesRequest a Technical Overview

U.S. Patent No. 12,377,109, Issued August 2025

2-Plus Year Stability Demonstrated. No Cold Chain Required.

Greater than 90% Intercalation Efficiency Validated

Greater than 90% Intercalation Efficiency Validated

2-Plus Year Stability Demonstrated. No Cold Chain Required.

Greater than 90% Intercalation Efficiency Validated

2-Plus Year Stability Demonstrated. No Cold Chain Required.

2-Plus Year Stability Demonstrated. No Cold Chain Required.

2-Plus Year Stability Demonstrated. No Cold Chain Required.

Who We Serve

Pharmaceutical and Biotech Partners

Pharmaceutical and Biotech Partners

Pharmaceutical and Biotech Partners

  Patented formulation technology ready for licensing. Pharmaceutical-grade excipients. No new chemical entities. Scalable from lab to commercial production. 

View our IP and licensing details

Cannabis and Wellness Manufacturers

Pharmaceutical and Biotech Partners

Pharmaceutical and Biotech Partners

Solve your CBDA, THCA, and CBGA shelf-life problem. Temperature-resilient. Precise dosing. Versatile delivery formats. 

See the stability data

Investors

Pharmaceutical and Biotech Partners

Investors

Patented platform technology at the intersection of cannabinoid science and pharmaceutical drug delivery. Led by the team behind FDA-approved Ryanodex. 

Meet the team

 Mingowood Pharmacal is a specialty pharmaceutical company that develops and licenses patented formulation technology for acidic cannabinoids. Our Intercalyx™ platform enables stable, scalable, and regulatory-compliant cannabinoid formulations across pharmaceutical, wellness, and consumer applications. We are actively seeking licensing partners in combination therapy development. Contact us to start the conversation. 

Mingowood Pharmacal

Copyright © 2024 Mingowood Pharmacal - All Rights Reserved.

Powered by

This website uses cookies.

We use cookies to analyze website traffic and optimize your website experience. By accepting our use of cookies, your data will be aggregated with all other user data.

Accept